"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333.
-
BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 07 18; 144(3):249-251.
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.
-
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023 08; 189:112926.
-
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
-
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.
-
Need for pneumococcal revaccination after blinatumomab therapy: A case report. Pediatr Blood Cancer. 2023 06; 70(6):e30237.
-
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
-
Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on av Integrins. J Mol Biol. 2021 07 23; 433(15):167090.
-
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 08; 56(8):1998-2004.